Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesMEX:IDXX 95 EV-to-FCF is 39.16 as of Jul. 15, 2026, which is 42% below its 10-year median of 67.23. GuruFocus rates MEX:IDXX with a GF Score™ of 95/100 and a GF Value™ of MXN11,014.76 (Modestly Undervalued). Among 99 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 70.71% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, IDEXX Laboratories's Enterprise Value is MXN763,051 Mil.
IDEXX Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN19,484 Mil. Therefore, IDEXX Laboratories's EV-to-FCF for today is 39.16.
The historical rank and industry rank for IDEXX Laboratories's EV-to-FCF or its related term are showing as below:
MEX:IDXX'
s EV-to-FCF Range Over the Past 10 Years
Min: 39.3 Med: 67.23 Max: 111.87
Current: 42.52
During the past 13 years, the highest EV-to-FCF of IDEXX Laboratories was 111.87. The lowest was 39.30. And the median was 67.23.
MEX:IDXX's EV-to-FCF is ranked worse than 70.71% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.47
vs MEX:IDXX: 42.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IDEXX Laboratories's PE Ratio (TTM) for today is calculated as:
IDEXX Laboratories's share price for today is MXN9810.00.
IDEXX Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN249.192.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
IDEXX Laboratories EV-to-FCF Related Terms
IDEXX Laboratories EV-to-FCF Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's EV-to-FCF falls into.
IDEXX Laboratories's current Enterprise Value is MXN763,051 Mil.
IDEXX Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN19,484 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (MEX:IDXX) has a EV-to-FCF of 39.16 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IDEXX Laboratories and its competitors. This is 42% below median its historical median of 67.23. Over the past decade, IDEXX Laboratories' EV-to-FCF has ranged from 39.30 to 111.87. According to the industry distribution chart, IDEXX Laboratories ranks #70 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 70.7%.
Is IDEXX Laboratories' EV-to-FCF too high?
IDEXX Laboratories' current EV-to-FCF of 39.16 is 42% below median its 10-year median of 67.23. Over the past 10 years, this metric has ranged from a low of 39.30 to a high of 111.87. The Medical Diagnostics & Research industry median EV-to-FCF is 25.47. IDEXX Laboratories' value of 39.16 is 53.7% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #70 out of 99 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EV-to-FCF compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #70 out of 99 companies for EV-to-FCF. This places IDEXX Laboratories in the lower half of its industry. The industry median EV-to-FCF is 25.47. IDEXX Laboratories' value of 39.16 is 53.7% above this benchmark. Historically, IDEXX Laboratories' own EV-to-FCF has ranged from 39.30 to 111.87 over the past decade. While the company's 10-year median is 67.23 vs. the industry median of 25.47, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 25.47, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current EV-to-FCF of 39.16 is 53.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 25.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EV-to-FCF is 39.16, which is 42% below median its own 10-year median of 67.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (MEX:IDXX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN11,014.76, compared to a current price of MXN9,810.00 — trading 10.9% below its estimated fair value. The current EV-to-FCF is 39.16, which is 42% below median its 10-year median of 67.23 and 53.7% above the Medical Diagnostics & Research industry median of 25.47. IDEXX Laboratories' overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For IDEXX Laboratories (MEX:IDXX), the current EV-to-FCF is 39.16 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (MEX:IDXX) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of MXN9,810.00 is trading 10.9% below its estimated GF Value™ of MXN11,014.76.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for MEX:IDXX:
EV-to-FCF: 39.16 (42% below median its 10-year median of 67.23)
GF Value™: MXN11,014.76 vs. price of MXN9,810.00 (10.9% below fair value)
Industry Position: 53.7% above the Medical Diagnostics & Research median (#70 of 99)
No single metric tells the full story. See the MEX:IDXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
95GF Score
Get the complete analysis for MEX:IDXX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IDXX has been successfully added to your 
